If you hate small brands, keep scrolling.

Congratulations to MSK's Dr. Joe Narus for being named to Crain's New York Business's list of Notable LGBTQIA+ Leaders! Dr. Narus manages nurse practitioners and physician assistants at MSK and specializes in care for the LGBTQIA+ population.

HAPPENING NOW: Neuro-oncologist Dr. Ingo Mellinghoff presents significant results from a phase III trial in patients with residual or recurrent grade 2 #glioma with an IDH1/2 mutation during the plenary session at #ASCO23 . The study: bit.ly/3CfTmy0

Leah Remini Mike Rinder Please have him contact David H. Ilson, MD, PhD at Memorial Sloan Kettering in NYC. He is the best expert in Esophageal Cancer. Let me know if I can help get him in.

Neuro-oncologist Dr. Ingo Mellinghoff shares what he’s most excited about today in #cancerresesrch at #ASCO23 .

Sher LGBTQ Nation Oh I'm sorry, I'm based in SCIENCE.

I studied evolution, biological function and behavior in college.

I was a zookeeper.

I managed a research lab for the chair of molecular biology at Memorial Sloan Kettering Cancer Institute for 5 years.

Nature is not black and white.

MSK #sarcoma oncologist Dr. Mrinal M. Gounder speaking during a panel at #ASCO23 . ASCO

Last day, best day. One more hour for some incredible MSK poster sessions at #ASCO23 .

Attendees at #ASCO23 are filing in to watch the plenary sessions, featuring two of our MSK researchers:

🔬 Neuro-oncologist Dr. Ingo Mellinghoff
🔬 Gastrointestinal oncologist Dr. Deb Schrag

Gastrointestinal oncologist Dr. Deb Schrag presents research that shows that people diagnosed with locally advanced #rectalcancer can be safely treated without radiation therapy. #ASCO23 . The study: bit.ly/3IW64Gh

Clinical geneticist Megha Ranganathan (Megha Ranganathan) discusses gender identity and cancer risk, specifically in transgender patients. #ASCO23

“This treatment may delay the need for radiation and chemotherapy for individuals with this disease,” says neuro-oncologist Dr. Ingo Mellinghoff, as he answers attendee questions following his plenary session. #ASCO23

“This has the potential to shift the treatment landscape of this disease,” says neuro-oncologist Dr. Ingo Mellinghoff, as he closes out his plenary session at #ASCO23 . #glioma

ULTRA MAGA Mike Forsythe April Lloyd MeidasTouch Maxwell Alejandro Frost Harry Sisson Chris Mowrey Dems of Gen Z David Hogg 🟧 The 2018 study has no relevance to the COVID-19 mRNA vaccines. Memorial Sloan Kettering Cancer Center confirmed the claim is false and misrepresents the findings of the study.

A lot of y’all be having one sided beefs.

Early diagnosis of Rheumatoid Arthritis (RA) can be challenging. Order the IdentRA® test panel, which combines 14-3-3η protein with RF and anti-CCP, for earlier, more accurate diagnosis of RA to guide prompt rheumatology referrals.

Breakthrough research in @nejm led by Dr. Ingo Mellinghoff found that #vorasidenib , an oral dual inhibitor of mutant IDH1/2 enzymes, significantly improved progression-free survival in patients with grade 2 diffuse gliomas, a type of #braintumor . #ASCO23 bit.ly/3CfTmy0

Join Dr. Robert Motzer (Robert Motzer MD) today as he discusses his abstract
- Subgroup analyses from the phase 3 CheckMate 914 (part A) trial - at #ASCO23 .

⏰ : 6/5 at 11:30am
📍: Hall D1

Learn more here: bit.ly/3MOrR3O

ASCO #MSKVoices

Can’t even wake an bake with Sloan Kettering this am 🙄 FML

Our Day 1️⃣ & 2️⃣ recap from the 2023 ASCO meeting. Lots more to come today and tomorrow. #ASCO23

Learn more about OncoKB™ at Booth 28161. #ASCO23 .